cyclic-gmp and Genital-Diseases--Male

This review study refers to the possibility to employ PDE5 inhibitors as an adjunct tool for the therapeutic management of male infertility. The literature tends to suggest that PDE5 inhibitors enhance the Leydig cell secretory function and play a role in the regulation of the contractility of the tunica albuginea and the epididymis. In addition, the literature suggests that PDE5 inhibitors increase the prostatic secretory function that results in an improvement in sperm motility in several cases. Some studies additionally demonstrate a role of PDE5 inhibitors in the regulation of sperm capacitation process. Additional placebo-controlled, randomized, blind studies are necessary to unequivocally suggest a therapeutic role of PDE5 inhibitors in the alleviation of semen disorders and male infertility.

Topics: Acrosome Reaction; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Epididymis; Genital Diseases, Male; Genitalia, Male; Humans; Infertility, Male; Leydig Cells; Male; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Semen; Seminiferous Tubules; Sertoli Cells; Sperm Capacitation; Spermatozoa; Testicular Diseases